362 related articles for article (PubMed ID: 29259102)
21. KLRG1 expression identifies short-lived Foxp3
Kornete M; Mason E; Istomine R; Piccirillo CA
Autoimmunity; 2017 Sep; 50(6):354-362. PubMed ID: 28850267
[TBL] [Abstract][Full Text] [Related]
22. Regulation of Diabetogenic Immunity by IL-15-Activated Regulatory CD8 T Cells in Type 1 Diabetes.
Stocks BT; Wilson CS; Marshall AF; Hoopes EM; Moore DJ
J Immunol; 2019 Jul; 203(1):158-166. PubMed ID: 31127035
[TBL] [Abstract][Full Text] [Related]
23. Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs.
Grinberg-Bleyer Y; Saadoun D; Baeyens A; Billiard F; Goldstein JD; Grégoire S; Martin GH; Elhage R; Derian N; Carpentier W; Marodon G; Klatzmann D; Piaggio E; Salomon BL
J Clin Invest; 2010 Dec; 120(12):4558-68. PubMed ID: 21099113
[TBL] [Abstract][Full Text] [Related]
24. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells.
Burchill MA; Yang J; Vogtenhuber C; Blazar BR; Farrar MA
J Immunol; 2007 Jan; 178(1):280-90. PubMed ID: 17182565
[TBL] [Abstract][Full Text] [Related]
25. Low TCR signal strength induces combined expansion of Th2 and regulatory T cell populations that protect mice from the development of type 1 diabetes.
Turner MS; Isse K; Fischer DK; Turnquist HR; Morel PA
Diabetologia; 2014 Jul; 57(7):1428-36. PubMed ID: 24737163
[TBL] [Abstract][Full Text] [Related]
26. Th1-Like ICOS+ Foxp3+ Treg Cells Preferentially Express CXCR3 and Home to β-Islets during Pre-Diabetes in BDC2.5 NOD Mice.
Kornete M; Mason ES; Girouard J; Lafferty EI; Qureshi S; Piccirillo CA
PLoS One; 2015; 10(5):e0126311. PubMed ID: 25946021
[TBL] [Abstract][Full Text] [Related]
27. Antidiabetic and Immunoregulatory Activities of Extract of
Lin CH; Kuo YH; Shih CC
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373070
[TBL] [Abstract][Full Text] [Related]
28. The CD137 Ligand Is Important for Type 1 Diabetes Development but Dispensable for the Homeostasis of Disease-Suppressive CD137
Foda BM; Ciecko AE; Serreze DV; Ridgway WM; Geurts AM; Chen YG
J Immunol; 2020 Jun; 204(11):2887-2899. PubMed ID: 32295876
[TBL] [Abstract][Full Text] [Related]
29. Thymically-derived Foxp3+ regulatory T cells are the primary regulators of type 1 diabetes in the non-obese diabetic mouse model.
Holohan DR; Van Gool F; Bluestone JA
PLoS One; 2019; 14(10):e0217728. PubMed ID: 31647813
[TBL] [Abstract][Full Text] [Related]
30. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors.
D'Alise AM; Auyeung V; Feuerer M; Nishio J; Fontenot J; Benoist C; Mathis D
Proc Natl Acad Sci U S A; 2008 Dec; 105(50):19857-62. PubMed ID: 19073938
[TBL] [Abstract][Full Text] [Related]
31. Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment.
Bresson D; Fousteri G; Manenkova Y; Croft M; von Herrath M
J Autoimmun; 2011 Dec; 37(4):342-51. PubMed ID: 22063316
[TBL] [Abstract][Full Text] [Related]
32. High Thymic Output of Effector CD4
Zhao Y; Alard P; Kosiewicz MM
J Immunol Res; 2019; 2019():8785263. PubMed ID: 31281853
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-2 and type 1 diabetes: new therapeutic perspectives.
Hartemann A; Bourron O
Diabetes Metab; 2012 Nov; 38(5):387-91. PubMed ID: 22771204
[TBL] [Abstract][Full Text] [Related]
34. Immunosuppressive therapy exacerbates autoimmunity in NOD mice and diminishes the protective activity of regulatory T cells.
Kaminitz A; Mizrahi K; Yaniv I; Stein J; Askenasy N
J Autoimmun; 2010 Sep; 35(2):145-52. PubMed ID: 20638242
[TBL] [Abstract][Full Text] [Related]
35. Genetic and functional data identifying Cd101 as a type 1 diabetes (T1D) susceptibility gene in nonobese diabetic (NOD) mice.
Mattner J; Mohammed JP; Fusakio ME; Giessler C; Hackstein CP; Opoka R; Wrage M; Schey R; Clark J; Fraser HI; Rainbow DB; Wicker LS
PLoS Genet; 2019 Jun; 15(6):e1008178. PubMed ID: 31199784
[TBL] [Abstract][Full Text] [Related]
36. Surge in regulatory T cells does not prevent onset of hyperglycemia in NOD mice: immune profiles do not correlate with disease severity.
Kaminitz A; Mizrahi K; Askenasy N
Autoimmunity; 2014 Mar; 47(2):105-12. PubMed ID: 24328490
[TBL] [Abstract][Full Text] [Related]
37. Age-dependent divergent effects of OX40L treatment on the development of diabetes in NOD mice.
Haddad CS; Bhattacharya P; Alharshawi K; Marinelarena A; Kumar P; El-Sayed O; Elshabrawy HA; Epstein AL; Prabhakar BS
Autoimmunity; 2016 Aug; 49(5):298-311. PubMed ID: 27245356
[TBL] [Abstract][Full Text] [Related]
38. A novel mechanism of regulatory T cell-mediated down-regulation of autoimmunity.
Qin HY; Mukherjee R; Lee-Chan E; Ewen C; Bleackley RC; Singh B
Int Immunol; 2006 Jul; 18(7):1001-15. PubMed ID: 16675487
[TBL] [Abstract][Full Text] [Related]
39. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment.
You S; Leforban B; Garcia C; Bach JF; Bluestone JA; Chatenoud L
Proc Natl Acad Sci U S A; 2007 Apr; 104(15):6335-40. PubMed ID: 17389382
[TBL] [Abstract][Full Text] [Related]
40. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes.
Tritt M; Sgouroudis E; d'Hennezel E; Albanese A; Piccirillo CA
Diabetes; 2008 Jan; 57(1):113-23. PubMed ID: 17928397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
